These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21789752)

  • 21. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
    Sampalis JS; Bissonnette S; Habib R; Boukas S;
    Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating hypertriglyceridemia.
    Röggla G; Fasan M; Kapiotis S
    CMAJ; 2007 Sep; 177(6):603; author reply 604-5. PubMed ID: 17846444
    [No Abstract]   [Full Text] [Related]  

  • 23. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating hypertriglyceridemia.
    Yavasoglu I; Kadikoylu G; Bolaman Z
    CMAJ; 2007 Sep; 177(6):603-4; author reply 604-5. PubMed ID: 17846443
    [No Abstract]   [Full Text] [Related]  

  • 26. Hypertriglyceridemia: management of atherogenic dyslipidemia.
    Bersot T; Haffner S; Harris WS; Kellick KA; Morris CM
    J Fam Pract; 2006 Jul; 55(7):S1-8. PubMed ID: 16822443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypertriglyceridemia--diagnostics, risk and treatment].
    Hexeberg S; Retterstøl K
    Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2746-9. PubMed ID: 15534665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
    Watts GF; Karpe F
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):987-97. PubMed ID: 21878044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Can cardiovascular events be prevented by raising HDL cholesterol?].
    Langslet G; Reikvam A
    Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating hypertriglyceridemia.
    Holub BJ
    CMAJ; 2007 Sep; 177(6):604; author reply 604-5. PubMed ID: 17846446
    [No Abstract]   [Full Text] [Related]  

  • 37. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.